Clinical observation of gemcitabine combined with S -1capsule on patients with advanced esophageal cancer
10.3969/j.issn.1002-3070.2014.01.006
- VernacularTitle:吉西他滨联合替吉奥胶囊治疗晚期食管癌患者的临床观察
- Author:
Liyuan JIANG
;
Caixia ZHAO
;
Yanguang FENG
;
Zhiyong CHENG
;
Ying HAN
- Publication Type:Journal Article
- Keywords:
Esophageal cancer;
S-1;
Gemcitabine;
Efficiency;
Toxicity
- From:
Practical Oncology Journal
2014;(1):30-33
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the efficiency and toxicities of Gemcitabine combined with S -1 cap-sule in the treatment of advanced esophageal cancer .Methods Twenty-nine patients with advanced esophageal cancer were treated with S-1 capsule 80 mg/m2 ,twice daily for 14 days and Gemcitabine (1 000 mg/m2 ) was in-travenously administrated on day 1 and 8.The chemotherapy was repeated every 21 days.After two consecutive treatment circles ,the short term efficacy ,adverse effects and follow -up condition were evaluated .Results One case showed complete remission (CR),11cases showed partial remission (PR),9 cases showed stable disease (SD),8 cases showed progressive disease(PD).The responsive rate(CR+PR)was 41.4%;the illness control rate(CR+PR+SD)was 72.4%.The major adverse events were myelosuppression ranging from grade Ⅰto Ⅲ, hand-foot syndrome,disgusting and the damage of liver function .Some patients displayed the damage of liver function.The median time to progress ( mTTP) was 6.9 months.The median 1-year survival rate was 64.3%. Conclusion The combination of Gemcitabine and S -1 capsule is an effective and well -tolerated method for the patients with advanced esophageal cancer .
